actions make these receptors a promising therapeutic candidate to address aberrant inflammation in stroke. 6 Of the 5 MCs identified, anti-inflammatory actions have been attributed primarily to MC 1 and MC 3 .
2 These receptors have both been shown to be expressed at varying levels in the brain and also on endothelial cells and immune cells (MC 1 expression on neutrophils; monocytes and macrophages; dendritic cells; natural killer cells and B lymphocytes. MC 3 expression on monocytes; macrophages and B lymphocytes). 2 However, the exact anti-inflammatory role of MC subtypes remains unclear, and may vary with the pathophysiological environment.
In this study, we use 2 distinct murine models of cerebral I/R to evaluate the dynamic recruitment of neutrophils in the cerebral microcirculation. Using both pharmacological and genetic approaches, we have demonstrated potent inhibitory actions of the MCs on cerebral leukocyte trafficking, and gained an insight into the relative importance of MC subtypes in mediating these effects.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

α-MSH Abrogates Neutrophil Recruitment After Cerebral I/R
To investigate leukocyte recruitment in the cerebral microvasculature, global ischemia was induced, followed by 40-minute reperfusion or 2-hour reperfusion and leukocyte to endothelial cell interactions in pial vessels were assessed by intravital microscopy ( Figure 1 ). Sham surgery, produced little to no leukocyte recruitment, however, I/R caused significant leukocyte rolling (191.0±31.49 cells/mm 2 per minute) and adherence (282.3±49.4 cells/mm 2 per minute), with 2-hour reperfusion resulting in a further significant increase in adhesion to 555.2±85.3 cells/mm 2 per minute ( Figure 1C ; Movies I and II in the online-only Data Supplement). Correlating with the observed effects on leukocyte recruitment was an enhanced serum soluble E-selectin by 2-hour reperfusion, as detected by ELISA, and a trend toward an increase in the number of intracellular adhesion molecule-1 (ICAM-1)-and vascular cellular adhesion molecule-1 (VCAM-1)-positive vessels detected in the brain. No effect was observed with respect to soluble P-selectin ( Figure II in the online-only Data Supplement). α-MSH (10 µg IP), a nonselective MC agonist, given at the start of reperfusion strongly inhibited leukocyte recruitment at 40 minutes, reducing rolling by 80% and adhesion by 68%, to levels comparable with sham animals. Furthermore, these protective effects remained highly significant even after 2 hours of reperfusion (Movie III in the online-only Data Supplement). In line with the reduced leukocyte recruitment at 2 hours, α-MSH was also found to reduce levels of soluble E-selectin and a modest reduction in vessel ICAM-1and VCAM-1 expression.
Finally, to ascertain the role of neutrophils, some mice were depleted of neutrophils before I/R. After I/R, neutropenic 
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Effect of α-MSH on NF-κB-Related Cytokine and mRNA Expression
The effect of cerebral I/R on serum cytokines was investigated using multicytokine analysis ( Figure IIIA -IIIC in the onlineonly Data Supplement). Expression of interleukin (IL)-12p70, interferon (IFN)-γ, and MCP-1 (monocyte chemoattractant protein) remained below the reliable detection range across all treatments (Data not shown). I/R induced a significant increase in serum tumor necrosis factor (TNF)-α by 2 hours, which was abolished by α-MSH treatment. The anti-inflammatory cytokine IL-10 showed a trend toward an increase at 2-hour reperfusion (to 34.7 pg/mL), but significantly increased (88.7 pg/mL) after α-MSH treatment. Levels of the pleotropic cytokine IL-6 remained unchanged after I/R, however, treatment with α-MSH was found to result in a significant upregulation of IL-6 by 2 hours. Considering IL-6 signaling via STAT3 has been shown to reduce neutrophil recruitment, 7 we also investigated levels of tyrosine 705 phosphorylated STAT3 in leukocyte nuclear fractions by Western blot, finding a slight enhancement of STAT3 in α-MSH-treated animals at 2 hours ( Figure IV in the online-only Data Supplement).
To investigate whether this influence over serum cytokines could be because of NF-κB inhibition, mRNA levels of the NF-κB regulatory protein IκB (which closely corresponds to NF-κB activation 8 ) were assessed in both blood and brain using quantitative reverse transcription polymerase chain reaction ( Figure IVA and IVB in the online-only Data Supplement). IκB levels were not significantly elevated 40 minutes after I/R, however by 2 hours, IκB was significantly increased in the blood, and this was suppressed by α-MSH treatment. Suppression of NF-κB activation in leukocytes at 2-hour reperfusion was further confirmed by Western blot analysis of serine 536 phophorylated NF-kB p65 in leukocyte nuclear fractions.
Effect of MC 1 and MC 3 Agonists on Neutrophil Recruitment and Circulating Cytokines
The relative contribution of MC subtypes on I/R-induced neutrophil recruitment was investigated using more selective MC agonists. Activation of MC 1 by BMS-470539 provided a potent inhibition of bilateral common carotid artery occlusion (BCCAo)-induced neutrophil rolling and adhesion at 40-minute reperfusion (Figure 2A and 2B), however, became less effective by 2 hours, with only the level of adhesion being significant versus vehicle. However, treatment with [DTRP 8 ]-γ-MSH, which has a high affinity for MC 3 , only inhibited cell adhesion at 40-minute reperfusion, yet by 2 hours this effect was stronger, with neutrophil rolling also being significantly reduced. Furthermore, [DTRP 8 ]-γ-MSH significantly reduced BCCAo-induced TNF-α release by 2 hours, while also elevating serum levels of the pleiotropic cytokine IL-6 and the anti-inflammatory IL-10 ( Figure 2C -2E).
Pharmacological Investigations Using the MC 3/4 Antagonist SHU9119
BMS-470539 is almost entirely selective for MC 1 , while [DTRP 8 ]-γ-MSH may activate other MCs than MC 3 . 9 To further examine the roles of specific MC subtypes, the MC 3/4 antagonist SHU9119 was coadministered with either α-MSH or [DTRP 8 ]-γ-MSH ( Figure 3C and 3D), revealing that MC 3/4 antagonism caused no increase in rolling or adhesion at 40-minute reperfusion versus α-MSH or [DTRP 8 ]-γ-MSH alone. In fact SHU9119 administered alone, or in conjunction with α-MSH, reduced neutrophil rolling. However, by 2 hours, coadministration of SHU9119 blunted the α-MSHinduced reductions in rolling and adhesion, and prevented the protective effects of [DTRP 8 ]-γ-MSH.
MC Receptor Expression
To determine whether the delayed importance of MC 3 was because of change in receptor expression antibody-based investigations into receptor expression were undertaken. However, initial analysis of MC 1 and MC 3 protein expression using Western blotting revealed antibody binding in MC 3 −/− mice, using both the Sigma Aldrich (M4937) and Acris (AP10124PU-N) MC 3 antibodies, despite polymerase chain reaction confirmation of the MC 3 −/− (Figure V in the onlineonly Data Supplement). This suggests that both antibodies tested display nonspecific binding to protein at a similar molecular weight to MC 3 , as has been previously described. 10 Therefore, quantitative reverse transcription polymerase chain reaction was used to quantify MC expression at the mRNA level. MC [1] [2] [3] [4] [5] was detected in both blood and brain, however, BCCAo induced no changes at either 40 minutes or 2 hours after BCCAo (Figure VI in the online-only Data Supplement).
Physiological Effects of MC1 and 3 in Cerebral I/R-Induced Inflammation
We tested whether the physiological effects of receptor deficiency would support our findings from pharmacological treatments. Recessive yellow (e/e) MC 1 mutant mice displayed enhanced (nearly 3×) neutrophil rolling at 40 minutes after I/R versus wild-type (WT; Figure 4A ) accompanied by elevated serum TNF-α ( Figure 4C ). In the absence of a functional MC 1 , α-MSH reduction of rolling was also hampered at this time point, however, e/e mice displayed no derangements in cell adhesion and were able to respond to α-MSH treatment. MC 3 null mice showed no significant differences in neutrophil recruitment, or in their ability to respond to α-MSH at 40 minutes. This is consistent with the predominat anti-inflammatory role of MC 1 at early reperfusion. In agreement with the diminished role of MC 1 observed in pharmacological studies at 2 hours, at this time point the inflammatory phenotype was not maintained, with TNF-α levels and neutrophil rolling and adhesion being comparable to WT ( Figure 5 ). 
Physiological Role in Focal Stroke Model
Stroke is highly variable in its severity and magnitude. The global model of cerebral I/R, represents human stroke conditions caused by atherosclerotic degeneration of the common carotid arteries and respiratory or cardiac arrest. To investigate whether the MC anti-inflammatory effects, we were observing were specific to global I/R, we also undertook investigations using a focal stroke model (ie, the middle cerebral artery occlusion model). We chose this model because of the fact that focal ischemia accounts for ≈80% of ischemic stroke. Figure 6 demonstrates that at 24 hours post ischemia while e/e mice showed elevated adhesion, MC 3 −/− displayed a more severe inflammatory phenotype with significantly enhanced rolling and adhesion. Importantly, the increased neutrophil recruitment observed, translated into elevated infarct volume and poor functional outcome (detected through neurological scoring) in animals with deficits in either receptor, suggesting both receptors to be potential pharmacological targets.
In Vitro Investigations of MC Effects on Neutrophil Functioning
The MC receptor system displays many disparities between humans and rodents and many MC agonists and antagonists have different selectivity in MCs from different species. 9, 11 To assess the effectiveness of MC treatments on human cells, we used the neutrophil flow chamber model and chemotaxis assay to investigate neutrophil inflammatory function ( Figure −/− sham and MC 3 −/− α-MSH groups n=3 all other groups n=4 mice/group. C, ELISA measurements of serum TNF-α levels n=3 mice/group and performed in duplicate. Statistical analysis was performed between mouse strains, within sham, or saline-treated groups to determine the phenotypic differences between strains, ‡Significance to WT P<0.01. Statistical analysis was also performed between sham, saline, and α-MSH treatment groups within the same strain. *Significance to sham group P<0.05 and †significance to salinetreated BCCAo group P<0.05. Figure 5 . The e/e mouse inflammatory phenotype is diminished by 2 hours. Wild-type (WT; C57BL/6; white bars) and e/e (lined bars) mice were subjected to sham or bilateral common carotid artery occlusion (BCCAo) and treated with saline or 10 µg α-melanocyte-stimulating hormone (MSH) at the start of reperfusion. Leukocyte recruitment was quantified at 2 hours of reperfusion in terms of: (A) rolling cell flux and (B) leukocyte adhesion (cells/ mm 2 per minute). n=4 mice/group for e/e saline group, and n=3 mice/group for sham and α-MSH e/e groups, comparisons were made with WT groups as in Figure 1 (n=6 mice/group). Statistical analysis was performed between mouse strains, within the same treatment group to evaluate phenotypic differences between strains. NS denotes no statistical significance to WT group. C, ELISA measurements of serum tumor necrosis factor (TNF-α) in WT and e/e mice. *Significance to sham groups P<0.01, †significance to BCCAo P<0.05.
Treating human umbilical vein endothelial cells (HUVECs)
with α-MSH (≤100 µg/mL), however, failed to induce significant reductions in neutrophil recruitment (data not shown), suggesting neutrophils to be the effector cells of MC actions in this context. In the chemotaxis assay, pretreatment with 10 µg/mL of α-MSH or [DTRP 8 ]-γ-MSH failed to inhibit neutrophil migration toward fMLP, however, BMS-470539 significantly reduced this response, suppressing the number of migrated cells by ≈75% ( Figure VIIB in the online-only Data Supplement), suggesting MC 1 to play a specific role in inhibiting neutrophil chemotaxis.
Discussion
This study provides, for the first time, evidence that MC treatments can effectively inhibit neutrophil recruitment in the unique microenvironment of the cerebral microvasculature. Using both selective ligands and MC mutant mice, we have gained an insight into MCs involved in modulating neutrophil recruitment in 2 separate models of cerebral I/R, finding both MC 1 and MC 3 to display important inhibitory roles. In addition, MC treatment was effective in modulating human neutrophil inflammatory functioning, and may represent a novel treatment to stem poststroke inflammation.
Both ischemic models used (BCCAo and middle cerebral artery occlusion) here resulted in a pronounced increase in neutrophil rolling and adhesion compared with sham, as has previously been observed. 12, 13 Nonselective treatment with α-MSH caused an abrogation of BCCAo-induced neutrophil rolling and adhesion, congruent with a trend toward a reduction in ICAM-1 and VCAM-1 expression in the cerebral vascular. Considering these effects were not significant, other adhesion molecules and integrin activation state may also play a role in the MC influence for leukocyte adhesion. Although anti-ICAM-1 antibody Enlimomab failed clinical trials for stroke (possibly because of inflammatory side effects to the mouse monoclonal antibody) strategies inhibiting CAMs have shown great promise preclinically. Soluble P-and E-selectin are early markers of endothelial activation. Although levels of soluble P-selectin were found only to produce a trend toward an increase after BCCAo, which was unchanged by treatment, soluble E-selectin was increased by 2 hours post ischemia. Elevated levels of soluble E-selectin have been demonstrated in human stroke and during sepsis.
14 In vitro studies have also shown that endothelial cells stimulated with IL-1β, TNF-α, endotoxin or serum deprivation, and TNF-α release E-selectin into the culture supernatant. 15, 16 α-MSH treatment significantly reduced BCCAo-induced soluble E-selectin, probably a reflection of reduced endothelial cell activation, consistent with the reduced levels of IL-1β and TNF-α observed.
Treatment also reduced serum TNF-α and IL-1β. IL-1β, in particular, plays a pivotal role in propagating inflammatory responses and is an established pathological factor in cerebrovascular disease, with significant preclinical and clinical evidence demonstrating blockade of IL-1β signaling to be beneficial in stroke. 17 MSH treatment also simultaneously enhanced anti-inflammatory IL-10 by 2-hour reperfusion. The ability of MCs to suppress proinflammatory responses while enhancing anti-inflammatory signals suggests that these receptors form an endogenous proresolving system. In humans, α-MSH concentrations increases in myocardial infarction and infection 2 and higher MC levels correlate with better outcome in patients wirh stroke. 18 Thus, given the results from this study the MC receptor system may prove a valuable therapeutic target for the treatment of stroke.
Although others have demonstrated a contribution of either MC 1 or MC 3 in providing anti-inflammatory protection in different systemic inflammatory models, we have, for the first time, identified protective roles for both receptors in the cerebral-microvasculature. In particular, we have identified that MC 1 -mediated effects predominate in early protection, while MC 3 actions are more delayed and induce proresolving factors. This study reveals an additional layer of complexity in MC inflammatory modulation, emphasizing the importance of drug treatment directed at both receptors.
Pharmacological investigations in the BCCAo model revealed the MC 1 agonist BMS-470539, significantly inhibited early neutrophil rolling and adhesion, while activation of MC 3 using [D-TRP 8 ]-γ-MSH only reduced adhesion. However, by 2 hours after BCCAo, despite a robust pharmacodynamic half-life of ≈8 hours, 19 BMS-470539 lost its inhibitory actions on rolling and the reduction of adhesion was diminished slightly. However at 2 hours, [D-TRP 8 ]-γ-MSH anti-inflammatory actions were enhanced. Thus suggesting MC 3 -mediated effects become more prominent at later time points. SHU9119 (MC 3/4 antagonist) was used to further explore the role of MC subtypes. By 40-minute reperfusion, SHU9119 enhanced, rather than inhibited, α-MSH and [D-TRP 8 ]-γ-MSH effects. Furthermore, administered alone, SHU9119 reduced neutrophil adhesion at 40 minutes, possibly because of its seldom reported agonist actions at MC 1/5 , 11 further supporting the predominance of MC 1 -mediated effects at early stages of reperfusion. By 2-hour reperfusion, SHU9119 lost these antiinflammatory effects, and cotreatments with SHU9119 inhibited the protective effects of α-MSH and [D-TRP 8 ]-γ-MSH, illustrating role for MC 3 in mediating delayed effects on neutrophil adhesion.
Despite the apparent change in MC engagement, no change in MC RNA expression was detected after BCCAo. Whether this is also reflected in protein expression is difficult to discern given the lack of specificity of the antibodies. 2 Given NF-κB DNA binding occurs only after 30 minutes after TNF-α stimulation, followed by gene transcription 30 minutes later, 8 NF-κB inhibition is unlikely to mediate the rapid effects on neutrophil recruitment at 40 minutes. Indeed, IκB transcript levels were not significantly increased at 40 minutes, yet by 2-hours blood IκB elevated 25-fold and nuclear levels of phosphorlyated NF-κB protein were enhanced, which was inhibited by α-MSH. Given our finding of the delayed effect of MC 3 -targeted treatment on neutrophil this later effect by α-MSH on IκB may be mediated predominantly via MC 3 signaling.
MC treatments inhibited neutrophil recruitment at 40 minutes after BCCAo, a timeframe incompatible with transcriptional changes. Such a phenomenon has previously been observed in other models; in zymosan-stimulated macrophages AP214 reduced IL-1β and TNF-α release with no effect on mRNA levels, 20 and α-MSH can act via MC 1 to shed cell surface CD14 on macrophages 21 and IL-8 receptors on neutrophils 22 independently of mRNA changes. Although the understanding of NF-κB-independent MC effects is still in its infancy, these mechanisms may fit well with the early efficacy of MC 1 treatments in suppressing neutrophil recruitment.
Differences in cytokine regulation between MC 1 -targeted activation and MC 3 -targeted/nonspecific activation further support the hypothesis that MC 1 23 while the anti-inflammatory cytokine IL-10 has been shown to be protective in several models of cerebral I/R. 24, 25 BMS-470539 treatments, however, had no effect on these NF-κB-controlled cytokines further supporting a distinct mechanism of action for the MC 1 -mediated early inhibition of neutrophil recruitment, while MC 3 may be more prominent in initiating proresolving effects. Conflicting reports have been made as the effect of MC treatments on IL-6 levels, however, in the current investigations both α-MSH and [D-TRP 8 ]-γ-MSH increased this pleiotropic cytokine at 2 hours, despite a decrease in NF-κB levels. As such the observed IL-6 release may be as a result of elevated release of presynthesized IL-6. α-MSH has previously been shown to influence IL-6 levels via MC 3 , 26 thus, explaining why IL-6 induction was not observed in BMS-470539-treated animals. Although IL-6 is an endogenous pyrogen with chemotactic activity, IL-6 knockout mice show no protection after experimental stroke. 27 Indeed IL-6 signaling via STAT3, has been shown to limit the inflammatory recruitment of neutrophils, 7 given that IL-10 may also activate STAT3 and levels were increased after α-MSH treatment such findings seem to be consistent with the present results. Furthermore, it has been demonstrated that NF-κB signaling may induce expression of IL-6 and IL-10 in cells with a high level of STAT3 phosphorylation. 28 In line with such observations, we found nuclear extracts from α-MSH-treated BCCAo animals to show a trend toward an elevation of phosphorylated STAT-3 protein.
Our investigations using MC mutant mice, in 2 independent models of stroke, further support a temporal difference in MC 1 animals displayed enhanced rolling and adhesion further supporting a delayed role of this receptor, while e/e animals only showed elevated adhesion compared with WT, perhaps as a result enhanced rolling before the observation period. Previous reports and unpublished data from our laboratory have shown no significant differences in the basal circulating levels of leukocytes between WT, e/e, and MC 3 −/− . 3 As such, the observed enhanced leukocyte recruitment is unlikely to be because of an initially high leukocyte count in these animals. As observed in BCCAo animals both receptors seem to be of importance with MC 3 anti-inflammatory circuits predominating at later time points.
Previously, Leoni et al 3 demonstrated that the MC 3 −/− mouse displays higher levels of leukocyte adhesion and emigration in the mesenteric microcirculation after I/R, while the response of the e/e mouse was not significantly different from WT. Yet in the same model, the MC 1 agonist BMS-470539 was effective in reducing leukocyte recruitment (an effect which was absent in e/e mice). 4 These results led the authors to postulate that the receptors show different physiological roles but that both may be harnessed pharmacologically. The present findings demonstrate a physiological role for both receptors in the cerebral microcirculation. Indeed, the observed of temporally distinct roles of these 2 receptors may help to explain such apparently conflicting findings across studies investigating the anti-inflammatory actions of these receptors. Crucially, our study demonstrates that the absence of signaling from either receptor resulted in enhanced infarct size and worse functional outcome compared with WT, further illustrating that both receptors are important pharmacological targets.
Our studies have further demonstrated that melancortin peptides may affect neutrophil inflammatory functioning in human cells. As the MC receptor system displays several disparities in organization and function between humans and rodents. Such as differences in potency and selectivity of MC ligands, and receptor expression between species, we also investigated MC roles in human neutrophil functioning. The facts that α-MSH treatment was found to suppress neutrophil recruitment to HUVECs via actions on neutrophils, and that MC 1 , but not MC 3 , is expressed on neutrophils supports the concept of an MC 1 -specific effect. These effects were rapid, occurring within 30 minutes after treatments, again a timeframe incompatible with transcriptional mechanisms. MC 1 -specific direct effects on neutrophils were further illustrated by the ability of MC 1 -targeted treatments to significantly reduce neutrophil chemotaxis (performed in the absence of other cell types). Further investigation, however, will need to be made to establish the effector cell type of the delayed, but potent, effects of MC 3 on neutrophil recruitment.
Taken together, novel experimental data presented here highlight a role for use of MC-based treatments as potential therapeutics for stroke, and potentially other neurovascular diseases. This work also demonstrates important roles for both MC 1 and MC 3 , showing MC 1 effects to provide rapid inhibition of leukocyte recruitment via mechanisms independent of NF-κB regulation, while MC 3 actions seem more robust at later time points. Given the complexity of MC regulation along with the variable nature of stroke, strategies targeting multiple MCs in a non(or perhaps partially) selective manner may be more fruitful in providing robust protection, rather than targeting 1 MC alone. Indeed, it may be telling that currently the most promising MC compounds (NDP-α-MSH and AP214) are both nonselective MC agonists. Further investigations into later time points of treatment and in animals with comorbidities will help to reveal the full potential of this promising therapeutic target for stroke.
